Chlorpropamide

Chlorpropamide
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alberto Plate [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Chlorpropamide is a 1st generation sulfonylurea and hypoglycemic agent that is FDA approved for the treatment of type 2 diabetes mellitus. Common adverse reactions include {{{adverseReactions}}}.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

There is limited information regarding Chlorpropamide FDA-Labeled Indications and Dosage (Adult) in the drug label.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Chlorpropamide in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Chlorpropamide in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding Chlorpropamide FDA-Labeled Indications and Dosage (Pediatric) in the drug label.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Chlorpropamide in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Chlorpropamide in pediatric patients.

Contraindications

Chlorpropamide tablets are contraindicated in patients with:

• Known hypersensitivity to any component of this medicine.
• Type 1 diabetes mellitus, diabetic ketoacidosis, with or without coma. This condition should be treated with insulin.

Warnings

Special Warning on Increased Risk of Cardiovascular Mortality

The administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. This warning is based on the study conducted by the University Group Diabetes Program (UGDP), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. The study involved 823 patients who were randomly assigned to one of four treatment groups (Diabetes, 19 [supp 2]:747-830, 1970).

UGDP reported that patients treated for 5 to 8 years with diet plus a fixed dose of tolbutamide (1.5 grams per day) had a rate of cardiovascular mortality approximately 2½ times that of patients treated with diet alone. A significant increase in total mortality was not observed, but the use of tolbutamide was discontinued based on the increase in cardiovascular mortality, thus limiting the opportunity for the study to show an increase in overall mortality. Despite controversy regarding the interpretation of these results, the findings of the UGDP study provide an adequate basis for this warning. The patient should be informed of the potential risks and advantages of chlorpropamide and of alternative modes of therapy.

Although only one drug in the sulfonylurea class (tolbutamide) was included in this study, it is prudent from a safety standpoint to consider that this warning may also apply to other oral hypoglycemic drugs in this class, in view of their close similarities in mode of action and chemical structure.

Adverse Reactions

Clinical Trials Experience

• Body as a Whole: Disulfiram-like reactions have rarely been reported with chlorpropamide
• Central and Peripheral Nervous System: Dizziness and headache.
• Hypoglycemia

Gastrointestinal: Gastrointestinal disturbances are the most common reactions; nausea has been reported in less than 5% of patients, and diarrhea, vomiting, anorexia, and hunger in less than 2%. Other gastrointestinal disturbances have occurred in less than 1% of patients including proctocolitis. They tend to be dose related and may disappear when dosage is reduced.

• Liver/Biliary: Cholestatic jaundice may occur rarely; chlorpropamide should be discontinued if this occurs. Hepatic porphyria and disulfiram-like reactions have been reported with chlorpropamide.
• Skin/Appendages: Pruritus has been reported in less than 3% of patients. Other allergic skin reactions, e.g., urticaria and maculopapular eruptions have been reported in approximately 1% or less of patients. These may be transient and may disappear despite continued use of chlorpropamide; if skin reactions persist the drug should be discontinued.
• As with other sulfonylureas, porphyria cutanea tarda and photosensitivity reactions have been reported. Skin eruptions rarely progressing to erythema multiforme and exfoliative dermatitis have also been reported.
• Hematologic Reactions: Leukopenia, agranulocytosis, thrombocytopenia, hemolytic anemia, aplastic anemia, pancytopenia, and eosinophilia have been reported with sulfonylureas.
• Metabolic/Nutritional Reactions: Hypoglycemia. Hepatic porphyria and disulfiram-like reactions have been reported with chlorpropamide.
• Endocrine Reactions: On rare occasions, chlorpropamide has caused a reaction identical to the syndrome of inappropriate antidiuretic hormone (ADH) secretion. The features of this syndrome result from excessive water retention and include hyponatremia, low serum osmolality, and high urine osmolality. This reaction has also been reported for other sulfonylureas.

Postmarketing Experience

There is limited information regarding Chlorpropamide Postmarketing Experience in the drug label.

Drug Interactions

There is limited information regarding Chlorpropamide Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): There is no FDA guidance on usage of Chlorpropamide in women who are pregnant.
Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Chlorpropamide in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Chlorpropamide during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Chlorpropamide in women who are nursing.

Pediatric Use

There is no FDA guidance on the use of Chlorpropamide in pediatric settings.

Geriatic Use

There is no FDA guidance on the use of Chlorpropamide in geriatric settings.

Gender

There is no FDA guidance on the use of Chlorpropamide with respect to specific gender populations.

Race

There is no FDA guidance on the use of Chlorpropamide with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Chlorpropamide in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Chlorpropamide in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Chlorpropamide in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Chlorpropamide in patients who are immunocompromised.

Administration and Monitoring

Administration

There is limited information regarding Chlorpropamide Administration in the drug label.

Monitoring

There is limited information regarding Chlorpropamide Monitoring in the drug label.

IV Compatibility

There is limited information regarding the compatibility of Chlorpropamide and IV administrations.

Overdosage

Overdosage of sulfonylureas including chlorpropamide can produce hypoglycemia. Mild hypoglycemic symptoms without loss of consciousness or neurologic findings should be treated aggressively with oral glucose and adjustments in drug dosage and/or meal patterns. Close monitoring should continue until the physician is assured that the patient is out of danger. Severe hypoglycemic reactions with coma, seizure, or other neurological impairment occur infrequently, but constitute medical emergencies requiring immediate hospitalization. If hypoglycemic coma is diagnosed or suspected, the patient should be given a rapid intravenous injection of concentrated (50%) glucose solution. This should be followed by a continuous infusion of a more dilute (10%) glucose solution at a rate that will maintain the blood glucose at a level above 100 mg/dL. Patients should be closely monitored for a minimum of 24 to 48 hours since hypoglycemia may recur after apparent clinical recovery.

Pharmacology

Error creating thumbnail: File missing
Template:Px
Chlorpropamide
Systematic (IUPAC) name
4-chloro-N-(propylcarbamoyl)benzenesulfonamide
Identifiers
CAS number	94-20-2
ATC code	A10BB02
PubChem	2727
DrugBank	DB00672
Chemical data
Formula	Template:OrganicBox atomTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox
Mol. mass	276.74 g/mol
SMILES	eMolecules & PubChem
Physical data
Melt. point	126–130 °C (259–266 °F)
Pharmacokinetic data
Bioavailability	>90%
Protein binding	90%
Metabolism	<1%
Half life	36 hours
Excretion	Renal (glomerular filtration → reabsorption → tubular secretion)
Therapeutic considerations
Licence data	US
Pregnancy cat.	C(AU) C(US)
Legal status	Prescription Only (S4)(AU) ?(CA) POM(UK) [[Prescription drug|Template:Unicode-only]](US)
Routes	Oral

Mechanism of Action

Chlorpropamide appears to lower the blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. The mechanism by which chlorpropamide lowers blood glucose during long-term administration has not been clearly established. Extrapancreatic effects may play a part in the mechanism of action of oral sulfonylurea hypoglycemic drugs. While chlorpropamide is a sulfonamide derivative, it is devoid of antibacterial activity.

Structure

There is limited information regarding Chlorpropamide Structure in the drug label.

Pharmacodynamics

There is limited information regarding Chlorpropamide Pharmacodynamics in the drug label.

Pharmacokinetics

There is limited information regarding Chlorpropamide Pharmacokinetics in the drug label.

Nonclinical Toxicology

There is limited information regarding Chlorpropamide Nonclinical Toxicology in the drug label.

Clinical Studies

There is limited information regarding Chlorpropamide Clinical Studies in the drug label.

How Supplied

There is limited information regarding Chlorpropamide How Supplied in the drug label.

Storage

There is limited information regarding Chlorpropamide Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Chlorpropamide |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Chlorpropamide |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Chlorpropamide Patient Counseling Information in the drug label.

Precautions with Alcohol

Alcohol-Chlorpropamide interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

There is limited information regarding Chlorpropamide Brand Names in the drug label.

Look-Alike Drug Names

There is limited information regarding Chlorpropamide Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

Chlorpropamide

Error creating thumbnail: File missing
Clinical data
[[Regulation of therapeutic goods |Template:Engvar data]]	US FDA: Chlorpropamide
ATC code	A10BB02 (WHO)
Pharmacokinetic data
Elimination half-life	36 hours
Identifiers
IUPAC name N-(4-chlorophenyl)sulfonylmethanamide
CAS Number	94-20-2
PubChem CID	2727
DrugBank	APRD00029
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C10H13ClN2O3S
Molar mass	276.741 g/mol

WikiDoc Resources for Chlorpropamide
Articles
Most recent articles on Chlorpropamide Most cited articles on Chlorpropamide Review articles on Chlorpropamide Articles on Chlorpropamide in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Chlorpropamide Images of Chlorpropamide Photos of Chlorpropamide Podcasts & MP3s on Chlorpropamide Videos on Chlorpropamide
Evidence Based Medicine
Cochrane Collaboration on Chlorpropamide Bandolier on Chlorpropamide TRIP on Chlorpropamide
Clinical Trials
Ongoing Trials on Chlorpropamide at Clinical Trials.gov Trial results on Chlorpropamide Clinical Trials on Chlorpropamide at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Chlorpropamide NICE Guidance on Chlorpropamide NHS PRODIGY Guidance FDA on Chlorpropamide CDC on Chlorpropamide
Books
Books on Chlorpropamide
News
Chlorpropamide in the news Be alerted to news on Chlorpropamide News trends on Chlorpropamide
Commentary
Blogs on Chlorpropamide
Definitions
Definitions of Chlorpropamide
Patient Resources / Community
Patient resources on Chlorpropamide Discussion groups on Chlorpropamide Patient Handouts on Chlorpropamide Directions to Hospitals Treating Chlorpropamide Risk calculators and risk factors for Chlorpropamide
Healthcare Provider Resources
Symptoms of Chlorpropamide Causes & Risk Factors for Chlorpropamide Diagnostic studies for Chlorpropamide Treatment of Chlorpropamide
Continuing Medical Education (CME)
CME Programs on Chlorpropamide
International
Chlorpropamide en Espanol Chlorpropamide en Francais
Business
Chlorpropamide in the Marketplace Patents on Chlorpropamide
Experimental / Informatics
List of terms related to Chlorpropamide

For patient information, click here

Chlorpropamide is an example of a drug class called sulphonylureas used to treat type 2 diabetes mellitus.

Mechanism of action

The sulphonylureas act mainly by augmenting insulin secretion and consequently are effective only when some residual pancreatic beta-cell activity is present; during long-term administration they also have an extrapancreatic action. All may cause hypoglycaemia but this is uncommon and usually indicates excessive dosage. Sulphonylurea-induced hypoglycemia may persist for many hours and must always be treated in hospital.

Sulphonylureas are considered for patients who are not overweight, or in whom metformin is contra-indicated or not tolerated. Several sulphonylureas are available and choice is determined by side-effects and the duration of action as well as the patient’s age and renal function. The long-acting sulphonylureas chlorpropamide and glibenclamide are associated with a greater risk of hypoglycaemia; for this reason they should be avoided in the elderly and shorter-acting alternatives, such as gliclazide or tolbutamide, should be used instead. Chlorpropamide also has more side-effects than the other sulphonylureas and therefore it is no longer recommended.

When the combination of strict diet and sulphonylurea treatment fails other options include:

combining with metformin(reports of increased hazard with this combination remain unconfirmed);

combining with acarbose, which may have a small beneficial effect, but flatulence can be a problem;

combining with pioglitazone or rosiglitazone

combining with bedtime isophane insulin but weight gain and hypoglycaemia can occur.

Insulin therapy should be instituted temporarily during intercurrent illness (such as myocardial infarction, coma, infection, and trauma). Sulphonylureas should be omitted on the morning of surgery; insulin is required because of the ensuing hyperglycaemia in these circumstances.

Cautions Sulphonylureas can encourage weight gain and should be prescribed only if poor control and symptoms persist despite adequate attempts at dieting; metformin is considered the drug of choice in obese patients. Caution is needed in the elderly and in those with mild to moderate hepatic and renal impairment because of the hazard of hypoglycaemia. The short-acting tolbutamide may be used in renal impairment, as may gliquidone and gliclazide which are principally metabolised in the liver, but careful monitoring of blood-glucose concentration is essential; care is required to choose the smallest possible dose that produces adequate control of blood glucose.

Contra-indications Sulphonylureas should be avoided where possible in severe hepatic and renal impairment and in porphyria. They should not be used while breast-feeding and insulin therapy should be substituted during pregnancy. Sulphonylureas are contra-indicated in the presence of ketoacidosis.

Side-effects Side-effects of sulphonylureas are generally mild and infrequent and include gastro-intestinal disturbances such as nausea, vomiting, diarrhoea and constipation.

Chlorpropamide has appreciably more side-effects, mainly because of its very prolonged duration of action and the consequent hazard of hypoglycemia and it should no longer be used. It may also cause facial flushing after drinking alcohol; this effect does not normally occur with other sulphonylureas. Chlorpropamide may also enhance antidiuretic hormone secretion and very rarely cause hyponatraemia (hyponatraemia is also reported with glimepiride and glipizide).

Sulphonylureas can occasionally cause a disturbance in liver function, which may rarely lead to cholestatic jaundice, hepatitis and hepatic failure. Hypersensitivity reactions can occur, usually in the first 6–8 weeks of therapy, they consist mainly of allergic skin reactions which progress rarely to erythema multiforme and exfoliative dermatitis, fever and jaundice; photosensitivity has rarely been reported with chlorpropamide and glipizide. Blood disorders are also rare but may include leucopenia, thrombocytopenia, agranulocytosis, pancytopenia, haemolytic anaemia, and aplastic anaemia.

Indications type 2 diabetes mellitus

Cautions see notes above. Also causes disulfiram-like reaction with alcohol

Contra-indications see notes above

Side-effects see notes above. Dose

Initially 250 mg daily with breakfast (elderly 100–125 mg but avoid—see notes above), adjusted according to response; max. 750 mg daily

Template:Oral hypoglycemics

Template:WikiDoc Sources